News Conference News ACC 2025 Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years L.A. McKeown March 30, 2025
News Conference News TCT 2023 Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials Michael O'Riordan October 24, 2023
News Conference News ACC 2022 Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years Michael O'Riordan April 04, 2022
News Conference News AHA 2017 DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy Yael L. Maxwell November 12, 2017